American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy
InfectologiaSobre o estudo
- Desenho
- Diretriz clínica
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Transplantation and cellular therapy
- Publicado em
- 21 mai 2025
- Citações
- 9
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy
Eleftheria Kampouri, Guy Handley, Tuan L Phan, Yeon Joo Lee, Ryan Shaw, Paul A Carpenter, Sanjeet S Dadwal, Roy F Chemaly, Genovefa A Papanicolaou, Masao Ogata et al.
Descritores MeSH
- Cell- and Tissue-Based Therapy
- Roseolovirus Infections
- Receptors, Chimeric Antigen
- Herpesvirus 6, Human
- Immunotherapy, Adoptive
- Hematopoietic Stem Cell Transplantation
- Humans
- Risk Factors
Veja também
Estudos relacionados
- HHV-6 reactivation in the era of CAR T-cell therapy: A systematic review of emerging challenges
- US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
- Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review
- Toxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis